Management issues in patients coinfected with hepatitis C virus and HIV

AIDS Reader

Volumn 12, Issue 1, 2002, Pages 19-21+24

  Bonacini, Maurizio ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Antiretroviral therapy; Hepatitis C virus; HIV AIDS; Interferon

Indexed keywords

ANTIVIRUS AGENT;

CONFERENCE PAPER; DISEASE COURSE; DISEASE DURATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PREVALENCE; SUPERINFECTION; VIRUS IDENTIFICATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS A VACCINES; HEPATITIS B VACCINES; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERONS; MALE; RIBAVIRIN; RNA, VIRAL; VACCINATION;

EID: 0036158033     PISSN: 10530894     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (25)

1. Hepatitis C in patients with human immunodeficiency virus infection: Diagnosis, natural history, meta-analysis of sexual and vertical transmission, and therapeutic issues
2. Hepatitis C in human immunodeficiency virus-coinfected patients: Increased variability in the hypervariable envelope coding domain
3. Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States
4. Combination therapy for hepatitis C infection
5. Natural history of liver fibrosis progression in patients with chronic hepatitis C
6. Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus
7. Activity of combination therapy with interferon alfa-2b plus ribavirin in chronic hepatitis C patients co-infected with HIV
8. Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA
9. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users
10. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C
11. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy
12. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection
13. Severe hepatic cytolysis: Incidence and risk factors in patients treated by antiretroviral combinations
14. Incidence of adverse reactions in HIV patients treated with protease inhibitors: A cohort study
15. Factors affecting liver fibrosis in human immunodeficiency virus and hepatitis C virus-coinfected patients: Impact of protease inhibitor therapy
16. Effect of HAART on liver related mortality in HIV/HCV coinfected patients
17. The safety and immunogenicity of hepatitis A vaccine (Havrix) in HIV+ patients: A double-blind, randomized, placebo-controlled trial
18. Hepatitis C and the British Columbia experience with hepatitis A vaccination
19. Hepatobiliary complications in patients with human immunodeficiency virus infection
20. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus
21. Efficacy and safety of combination therapy with interferon plus ribavirin in HIV-infected patients with chronic hepatitis
22. Interferon alfa-2b/ribavirin combination therapy in HIV/HCV coinfected persons: Results of a multicenter randomized double-blind controlled trial
23. Efficacy of pegylated interferon alfa-2a (PEGASYS) in randomized trials of patients with chronic hepatitis C, with and without cirrhosis: Correlation of virological responses with baseline histology and genotype
24. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
25. Once weekly epoietin alfa increases hemoglobin and decreases RBV discontinuation among HCV patients who develop anemia on RBV/INF therapy